Selective thrombolysis in acute deep vein thrombosis: Evaluation of adjuvant therapy in vivo

CardioVascular and Interventional Radiology

Volumn 22, Issue 5, 1999, Pages 403-410

  Roy, Sumit ^a   Brosstad, Frank ^b   Sakariassen, Kjell S ^c,d  

^a UNIVERSITY OF OSLO   (Norway)

^b OSLO UNIVERSITY HOSPITAL   (Norway)

^c UNIVERSITY OF OSLO   (Norway)

^d PFIZER INC   (United States)

Author keywords

Thrombolysis, catheter directed; Thrombolysis, comparative studies; Thrombolysis, venous; Thrombosis, experimental; Veins, thrombosis

Indexed keywords

ALTEPLASE; ANTITHROMBIN; DALTEPARIN; FIBRINOGEN; FIBRINOLYTIC AGENT; GLYCERYL TRINITRATE; HEPARIN; ILOPROST; PROTHROMBIN; THROMBOPLASTIN; THROMBOSTAT; TISSUE PLASMINOGEN ACTIVATOR; UNCLASSIFIED DRUG;

ADJUVANT THERAPY; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BOLUS INJECTION; CONTROLLED STUDY; DEEP VEIN THROMBOSIS; DRUG EFFICACY; FIBRINOGEN BLOOD LEVEL; FIBRINOLYTIC THERAPY; HEPARINIZATION; ILIAC VEIN; IMPLANTABLE PORT SYSTEM; INTRAVENOUS DRUG ADMINISTRATION; NONHUMAN; PARTIAL THROMBOPLASTIN TIME; PRIORITY JOURNAL; PROTHROMBIN TIME; SWAN GANZ CATHETER; SWINE;

EID: 0032822796     PISSN: 01741551     EISSN: None     Source Type: Journal    
DOI: 10.1007/s002709900415     Document Type: Article

References (59)

1. Semba CP, Dake M (1994) Iliofemoral deep venous thrombosis: Aggressive therapy with catheter-directed thrombolysis. Radiology 191: 487-494
2. Bjarnason H, Kruse JR, Asinger DA, Nazarian GK, Dietz CA Jr, Caldwell MD, Key NS, Hirsch AT, Hunter DW (1997) Iliofemoral deep vein thrombosis: Safety and efficacy outcome during 5 years of catheter-directed thrombolytic therapy. J Vasc Interv Radiol 8:405-418
3. Théry C, Bauchart JJ, Lesenne M, Asseman P, Flajollet JG, Legghe R, Marache P (1992) Predictive factors of effectiveness of streptokinase in deep venous thrombosis. Am J Cardiol 69:117-122
4. Mewissen MW (1997) Catheter-directed thrombolytic therapy of the lower extremity: Interim data report from the data collection center. J Vasc Interv Radiol 8[Suppl]:50-52
5. Diamond SL, Anand A (1993) Inner clot diffusion and permeation during fibrinolysis. Biophys J 65:2622-2643
6. Roy S, Lærum F, Brosstad F (1998) Quantitative evaluation of thrombolysis techniques: Influence of catheter characteristics and delivery parameters. Cathet Cardiovasc Diagn 43:111-119
7. Gulba DC, Barthels M, Westhoff-Bleck M, Jost S, Rafflenbeul W, Daniel WG, Hecker H, Lichtlen PR (1991) Increased thrombin levels during thrombolytic therapy in acute myocardial infarction: Relevance for the success of therapy. Circulation 83:937-944
8. Girbel PA, Serebarunay VL, Shustov AR, Bahr RD, Carpo C, Ohman EM, Topol EJ (for GUSTO-III investigators) (1998) Effects of reteplase and alteplase on platelet aggregation and major receptor expression during the first 24 hours of acute myocardial infarction treatment. J Am Coll Cardiol 31:1466-1473
9. Rudd MA, George D, Amarante P, Vaughan DE, Loscalzo J (1990) Temporal effects of thrombolytic agents on platelet function in vivo and their modification by prostaglandins. Circ Res 67:1175-1181
10. Valji K, Bookstein JJ (1992) Efficacy of adjunctive intrathrombic heparin with pulse spray thrombolysis in rabbit inferior vena cava thrombosis. Invest Radiol 27:912-917
11. Fareed J, Jeske W, Eschenfelder V, Iqbal O, Hoppensteadt D, Ahsan A (1996) Preclinical studies on a low molecular weight heparin. Thromb Res 81[Suppl]:S1-S27
12. Weitz JI (1997) Low-molecular-weight heparins. N Engl J Med 337: 688-698
13. Bithell TC (1993) Blood coagulation. In: Lee GR, Bithell TC, Foerster J, Athens JW, Luker JN (eds) Wintrobe Clinical Hematology, 9th edn, vol 1. Lea & Febiger, Philadelphia, pp 566-615
14. 1, and nitroglycerin. Circ Res 65:796-804
15. 1 accelerates thrombolysis by tissue plasminogen activator. Blood 73:1213-1217
16. Chirkov YY, Naujalis JI, Sage RE, Horowitz JD (1993) Antiplatelet effects of nitroglycerin in healthy subjects and in patients with stable angina pectoris. J Cardiovasc Pharmacol 24:384-389
17. 1 plus streptokinase in acute myocardial infarction. Am J Cardiol 58:1161-1166
18. Nichols WW, Nicolini FA, Khan S, Saldeen TGP, Mehta JL (1993) Failure of prostacyclin analog iloprost to sustain coronary blood flow after recombinant tissue-type plasminogen-induced thrombolysis in dogs. Am Heart J 126:285-292
19. 1 during pulse-spray thrombolysis with tissue-type plasminogen activator in experimental thrombosis. Radiology 186:873-876
20. Werns SW, Rote WE, Davis JH, Guevara T, Lucchesi BR (1994) Nitroglycerin inhibits experimental thrombosis and reocclusion after thrombolysis. Am Heart J 127:727-737
21. Korrowski R, Chemine A, Hasdai D, Ovadia Z, Battler A (1995) Beneficial effects of nitroglycerin on arterial thrombosis after thrombolysis: Results from a rabbit thrombosis model. Eur Heart J 16:177-183
22. Nicolini FA, Ferrini D, Ottani F, Galvani M, Ronchi R, Behrens PH, Rusticali F, Mehta JL (1994) Concurrent nitroglycerin therapy impairs tissue-type plasminogen activator-induced thrombolysis in patients with acute myocardial infraction. Am J Cardiol 74:662-666
23. Roy S, Lærum F, Brosstad F, Kvernebo F, Sakariassen KS (1998) Animal model of acute deep vein thrombosis. Cardiovasc Intervent Radiol 21:329-333
24. Roy S, Lærum F, Brosstad F, Kvernebo K, Sakariassen KS (1997) Percutaneous treatment of acute deep vein thrombosis with "sequestrated thrombolysis." (abstract) Cardiovasc Intervent Radiol 20[Suppl 1]:S112
25. Ludbrook L (1994) Repeated measurements and multiple comparisons in cardiovascular research. Cardiovasc Res 28:303-311
26. Young E, Wells P, Holloway S, Weitz J, Hirsh J (1994) Ex-vivo and in-vivo evidence that low molecular weight heparins exhibit less binding to plasma proteins than unfractionated heparin. Thromb Haemost 71:300-304
27. Hoppensteadt DA, Jeske W, Fareed J, Bermes EW JR (1995) The role of tissue factor pathway inhibitor in the mediation of antithrombotic actions of heparin and low molecular weight heparins. Blood Coagul Fibrinolysis 6[Suppl]:S57-S64
28. Falkon L, Garí M, Barbanoj M, Amiral J, Fontcuberta J (1998) Tissue factor pathway inhibitor and anti-FXa kinetic profiles of a new low-molecular-mass heparin, Bemiparin, at therapeutic subcutaneous doses. Blood Coag Fibrinolysis 9:137-141
29. Montalescot G, Philippe F, Ankri A, Vicaut E, Bearez F, Poulard JE, Carrie D, Flammang D, Dutoit A, Carayon A, Jardel C, Chevot M, Bastard JP, Bigonzi F, Thomas D (1998) Early increase of von Wille-brand factor predicts adverse outcome in unstable coronary artery disease: Beneficial effects of enoxaparin. Circulation 98:294-299
30. Antman EM, Handin R (1998) Low-molecular-weight heparins: An intriguing new twist with profound implications. Circulation 98:287-289
31. Bacher P, Welzel D, Iqbal O, Hoppensteadt D, Callas D, Walenga JM, Fareed J (1992) The thrombolytic potency of LMW-heparin compared to urokinase in rabbit jugular vein clot lysis model. Thromb Res 66:151-158
32. Nilsen DWT, Gøransson L, Larsen A-I, Hetland Ø, Kierulf P (1997) Systemic thrombin generation and activity resistant to low molecular weight heparin administered prior to streplokinase in patients with acute myocardial infarction. Thromb Haemost 77:57-61
33. Grosset AB, Spiro TE, Beynon J, Rodgers GM (1997) Enoxaparin, a low-molecular weight heparin suppresses prothrombin activation more effectively than unfractionated heparin in patients treated for venous thromboembolism. Thromb Res 86:349-354
34. Wolzt M, Eder M, Weltermann A, Entlicher J, Eichler H-G, Kyrle PA (1997) Comparison of the effects of different low molecuar weight heparins on the haemostatic system activation in man. Thromb Haemost 78:876-879
35. Stassen J-M, Rappold HJ, Valinthout I, Collen D (1993) Comparative effects of enoxaparin and heparin on arterial and venous clot lysis with alteplase in dogs. Thromb Haemost 69:454-459
36. Melissari E, Monte G, Lindo VS, Pemberton KD, Wilson NV, Edmondson R, Das S, Kakker VV (1992) Congenital thrombophilia among patients with venous thromboembolism. Blood Coagul Fibrinolysis 3:749-758
37. Finazzi G, Barbui T (1994) Different incidence of venous thrombosis in patients with inherited deficiencies of antithrombin III, protein C and protein S. Thromb Haemost 71:15-18
38. Humphries JE (1993) Acquired antithrombin III deficiency: Replacement with antithrombin III concentrates in a patient with protein S deficiency accelerates response to therapy. Acta Haematol 90:151-154
39. Patton DF, Harper JL, Wooldridge TN, Gordon BG, Coccia P, Haire WD (1996) Treatment of veno-occlusive disease of the liver with bolus tissue plasminogen activator and continuous infusion of antithrombin III concentrate. Bone Marrow Transplant 17:443-447
40. Grip L, Blömback M, Egberg N, Olsson Å, Svane B, Velander M (1997) Antithrombin III supplementation for patients undergoing PTCA for unstable angina pectoris: A controlled randomized double-blind pilot study. Eur Heart J 18:443-449
41. Reiter W, Ehrensberger H, Steinbrückner B, Keller F (1995) Parameters of haemostasis during acute venous thrombosis. Thromb Haemost 74:596-601
42. Balk R, Emerson T, Fourrier F, Kruse JA, Mammen EF, Schuster H-P, Vinazzer H (1998) Therapeutic use of antithrombin concentrate in sepsis. Semin Thromb Hemost 24:183-194
43. Schächinger V, Allert M, Kasper W, Just H, Vach W, Zeiher AM (1994) Adjunctive intracoronary infusion of antithrombin III during percutaneous transluminal coronary angioplasty: Results of a prospective, randomized trial. Circulation 90:2258-2266
44. 2) induced disaggregation of ADP aggregated platelets. Prostaglandins Leukotrienes Med 4:385-397
45. Schafer AI, Zavoico GB, Loscalzo J, Maas AK (1987) Synergistic inhibition of platelet activation by plasmin and prostaglandin. Blood 69:1504-1507
46. Iocaviello L, de Curtis A, d'Amato MC, Amore C, Buczko W, de Gaetano G, Donati MB (1994) Prostacyclin is required for t-PA release after venous occlusion. Am J Physiol 266:H429-H434
47. Darius H, Binz C, Veit K, Fisch A, Meyer J (1995) Platelet receptor desensitization induced by elevated prostacyclin levels causes platelet endothelial cell adhesion. J Am Coll Cardiol 26:800-806
48. MacDermot J (1986) Desensitization of prostacyclin responsiveness in platelets: Apparent differences in the mechanism in vitro and in vivo. Biochem Pharmacol 35:2645-2649
49. Becker RC, Corrao JM, Bovill EG, Gore JM, Baker SP, Miller ML, Lucas FV, Alpert JA (1990) Intravenous nitroglycerin-induced heparin resistance: A qualitative antithrombin III abnormality. Am Heart J 119:1254-1261
50. Brack MJ, More RS, Hubner PJB, Gershlick AH (1993) The effect of low dose nitroglycerine on plasma heparin concentrations and activated plasma thromboplastin times. Blood Coag Fibrinolysis 4:183-186
51. Villanueva GB, Parret Y, Danishefsky I (1980) Tryptophan residue at the tryptophan binding site of antithrombin III. Arch Biochem Biophys 203:453-457
52. Thomas GR, Thibodeaux H, Errett CJ, Badillo JM, Wu DT, Renfino CJ, Key BA, Bennett WF (1996) Limiting systemic plasminogenolysis reduces the bleeding potential for tissue-type plasminogen activators but not for streptokinase. Thromb Haemost 75:915-920
53. Bounameaux H, Banga JD, Bluhmki E, Coccheri S, Fiessinger J-N, Haarmann W, Lockner D, Mahler F, Ninet J, Schneider P-A, de Torrente A, van der Meer J, Verhaeghe R (1992) Double-blind, randomized comparison of systemic continuous infusion of 0.25 versus 0.50 mg/kg/24 h of alteplase over 3-7 days for treatment of deep venous thrombosis: Results of the European Thrombolysis with rt-PA in Venous Thrombosis (ETTT) Trial. Thromb Haemost 67:306-309
54. 2 in vitro. Naunyn Schiemedebergs Arch Pharmacol 316:252-255
55. Kovacs IB, Mayou SC, Kirby JD (1991) Infusion of a stable prostacyclin analogue, iloprost, to patients with peripheral vascular disease: Lack of antiplatelet effect but risk of thrombosis. Am J Med 90:41-45
56. Kamikubo Y, Hamuro T, Takemoto S, Nakahara Y, Kamei S, Nakagaki T, Miyamoto S, Funatsu A, Kato H (1998) A kinetic analysis of the interaction of human recombinant tissue factor pathway inhibitor with factor Xa utilizing an immunoassay and the effect of antithrombin III/heparin on the complex formation. Thromb Res 89:179-186
57. Laake K (1974) Cold-promoted activation of factor VII in human plasma: Studies on associated acyl arginine esterase activity. Thromb Res 4:769-774
58. Collen D (1988) Synergism of thrombolytic agents: Investigational procedures and clinical potential. Circulation 77:731-735
59. Bagge L, Wahlberg T, Holmer E, Tydén H, Nyström SO (1994) Low-molecular-weight-heparin (Fragmin) versus heparin for anticoagulation during cardiopulmonary bypass in open heart surgery using a pig model. Blood Coag Fibrinolysis 5:265-272